The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Hepatitis C and Coronary Artery Disease Linked

Back to News Homepage

Next

HCV Management Pearl: Teeth Grinding and Its Aggravator

NS5B Polymerase Inhibitors to Begin Hep C Trials

December 15, 2011

Print this page

Two Hepatitis C Phase 1 studies are set to evaluate the safety and tolerability of NS5B polymerase inhibitors from Vertex and Alios BioPharma.

Vertex, Alios BioPharma commence studies for Hepatitis C treatment

PBR Staff Writer

Published 12 December 2011

Vertex Pharmaceuticals and Alios BioPharma, together have initiated two clinical studies for the nucleotide analogues ALS-2200 and ALS-2158, inhibitors of the hepatitis C NS5B polymerase.

ALS-2200 and ALS-2158 are pan-genotypic nucleotide analogues, designed to inhibit the replication of the hepatitis C virus by acting on the NS5B polymerase.

The two Phase 1 studies will be randomized, double-blind, placebo-controlled studies, with the primary goals of evaluating the safety and tolerability of single ascending doses of ALS-2200 and ALS-2158 in healthy volunteers and of multiple ascending doses in people with chronic genotype-1 hepatitis C.

Continue reading this entire article:
http://contractresearch.pharmaceutical-business-review.com/news/vertex-alios-biopharma-commence-studies-for-hepatitis-c-treatment-121211

No Comments - be the first!
Share
Share

Previous

Hepatitis C and Coronary Artery Disease Linked

Back to News Homepage

Next

HCV Management Pearl: Teeth Grinding and Its Aggravator

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.